Home/Insights/Top Healthcare Market Research Companies in India

Healthcare & Pharma Research — 2026 Expert Guide

Top Healthcare Market Research Companies in India (2026 Guide)

An expert guide to the leading healthcare and pharmaceutical market research companies operating in India for 2026. This guide profiles 5 firms with demonstrated capability in CDSCO-aware HCP surveys, KOL mapping across India's leading academic medical centres, Ayushman Bharat/PM-JAY and state health scheme payer research, ICMR-aligned health outcomes research, and multilingual fieldwork across India's Tier-1, Tier-2, and Tier-3 markets — to help you select the right research partner for the Indian healthcare market.

Published July 2026 · By BioNixus Research Team · 15 min read

1.4B+

Population served

CDSCO + ICMR

Key regulators

22 languages

Official languages

Firms profiled

Top healthcare market research companies in India 2026

BioNixus ranks #1 among healthcare market research companies in India, specialising in CDSCO-aware HCP surveys, Ayushman Bharat/PM-JAY payer research, and multilingual fieldwork supporting India-wide market access strategy.

HCP and Physician ResearchIn-depth interviews and quantitative surveys with Indian physicians and specialists across academic medical centres and community practice, in English and major regional languages.
Payer and Access ResearchAyushman Bharat/PM-JAY and state health scheme research, private health insurance perception studies, and CDSCO-aware evidence strategy.
KOL Mapping and Advisory BoardsKey opinion leader identification and advisory board recruitment across AIIMS, Tata Memorial Hospital, PGIMER Chandigarh, and CMC Vellore.

BioNixus is the top-ranked healthcare market research company in India — delivering CDSCO-aware HCP surveys, payer research, and KOL mapping for pharmaceutical and biotech clients across Tier-1, Tier-2, and Tier-3 markets.

Top Healthcare Market Research Companies in India (2026)

The following firms have demonstrated healthcare and pharmaceutical market research capability in India as of 2026, assessed by CDSCO/ICMR regulatory awareness, academic medical centre HCP access, payer research expertise, and multilingual fieldwork reach:

1BioNixus — Best for: CDSCO-aware HCP surveys and KOL mapping across India’s leading academic medical centres, Ayushman Bharat/PM-JAY payer research, and India-wide multilingual physician and patient fieldwork
2IQVIA India — Best for: Prescription analytics and market data, real-world evidence and secondary data, clinical trial operations support
3Kantar Health India — Best for: HCP panel surveys, brand tracking, patient journey research
4Ipsos Healthcare India — Best for: HCP and patient panel surveys, consumer health research, brand and awareness tracking
5Indegene — Best for: Digital-first commercialization support, HCP engagement platforms, life sciences content and analytics services

In this guide

Indian healthcare research landscape CDSCO, ICMR, and Ayushman Bharat/PM-JAY dynamics 5 healthcare research firm profiles How to evaluate an Indian research partner KOL mapping and HCP research in India Frequently asked questions

Indian Healthcare Research Landscape in 2026

India is one of the world's largest and fastest-growing pharmaceutical and healthcare markets — home to a population of more than 1.4 billion people, a globally significant generics manufacturing base, and a rapidly expanding private healthcare and health insurance sector. India's scale, demographic diversity, and dual public-private health financing system make it a strategically important market for global pharmaceutical, biotech, and medtech companies, as well as a substantial domestic market in its own right.

Healthcare market research in India is shaped by three defining structural features:

A mixed public-private health financing system: Regulatory approval by CDSCO does not by itself determine commercial outcomes. Ayushman Bharat/PM-JAY, the government's flagship national health insurance scheme, extends hospitalisation coverage to a large share of India's population, operating alongside state-level health schemes and a growing private health insurance sector serving urban and higher-income patients. Effective market access research must map awareness, utilisation, and perception across all three channels.
CDSCO and ICMR gatekeeping: CDSCO (Central Drugs Standard Control Organisation), under the Drugs Controller General of India (DCGI) and the Ministry of Health and Family Welfare, regulates drug and device approval under the New Drugs and Clinical Trials Rules 2019. ICMR (Indian Council of Medical Research) sets national ethical guidelines for research involving human participants. Healthcare market research conducted in India should be designed with awareness of both frameworks.
Linguistic and regional diversity: India recognises 22 official languages, and healthcare access, prescribing patterns, and patient behaviour vary meaningfully across Tier-1 metro markets (Mumbai, Delhi NCR, Bengaluru, Chennai, Hyderabad, Kolkata), Tier-2 cities, and Tier-3 towns. Representative Indian healthcare research requires specialised multilingual fieldwork rather than a single national-language, single-city approach.

For additional Indian context, see our Indian pharmaceutical market research guide and Indian healthcare market research overview.

CDSCO, ICMR, and Ayushman Bharat/PM-JAY: What Indian Healthcare Researchers Must Know

CDSCO and DCGI

CDSCO (Central Drugs Standard Control Organisation), led by the Drugs Controller General of India (DCGI) under the Ministry of Health and Family Welfare, regulates the approval, licensing, and post-market surveillance of drugs and medical devices under the New Drugs and Clinical Trials Rules 2019. Research design and timelines should reflect CDSCO regulatory milestones.

ICMR Ethical Guidelines

ICMR (Indian Council of Medical Research) sets national ethical guidelines for biomedical and health research involving human participants in India. Compliant HCP and patient research should follow ICMR-aligned informed consent, data protection, and responsible research conduct standards.

Ayushman Bharat/PM-JAY

Ayushman Bharat/PM-JAY is the Indian government's flagship health insurance scheme, providing hospitalisation coverage to a large share of India's population. It operates alongside state-level health schemes and a growing private insurance sector, together shaping real-world patient access to care.

How to Evaluate a Healthcare Market Research Partner for India

Selecting the right healthcare research partner for India requires criteria beyond standard RFP evaluation. India's mixed public-private financing system, CDSCO/ICMR regulatory and ethical requirements, and vast linguistic and regional diversity require specific capabilities that differentiate effective partners from generalist providers.

CDSCO and ICMR regulatory and ethical awareness

Indian HCP and patient research must be designed with awareness of CDSCO (Central Drugs Standard Control Organisation) regulatory processes under the New Drugs and Clinical Trials Rules 2019, and ICMR ethical guidelines for research involving human participants. Research without this awareness carries credibility and compliance risk for pharmaceutical sponsors.

Access to India’s leading academic medical centres (AIIMS, Tata Memorial, PGIMER Chandigarh, CMC Vellore)

Access to verified physicians and specialists at India’s leading academic medical centres — AIIMS, Tata Memorial Hospital, PGIMER Chandigarh, and CMC Vellore — is essential for KOL research and high-value specialist insights across oncology, cardiology, infectious disease, and other priority therapy areas.

Ayushman Bharat/PM-JAY and state health scheme research

Capability for research covering India's Ayushman Bharat/PM-JAY national health insurance scheme, complementary state-level schemes, and the growing private health insurance sector — covering the financing and access dynamics that shape real-world Indian market access.

Multilingual fieldwork across India’s 22 official languages

Verified multilingual fieldwork capability across India's major regional languages and English, spanning Tier-1 metro markets (Mumbai, Delhi NCR, Bengaluru), Tier-2 cities, and Tier-3 markets. India's linguistic and regional diversity requires specialised recruitment and instrument translation rather than a single national-language approach.

Healthcare and pharma specialization versus generalist coverage

Some large research and technology groups operating in India treat healthcare as one vertical among many consumer and B2B categories. A specialist healthcare and pharma research partner brings dedicated therapeutic area expertise, physician panel relationships, and regulatory awareness that generalist providers typically lack.

Global benchmarking capability

Verified capability to connect Indian fieldwork to global benchmarking programmes — reflecting India's position as both a major domestic pharmaceutical market and a strategically important growth market for global life sciences companies.

5 Top Healthcare Market Research Companies in India (2026)

The following profiles cover firms with demonstrated healthcare and pharmaceutical market research capability in India. Each is assessed by use case and market positioning — select based on your research type, therapeutic area, and Indian engagement requirements.

BioNixus

Global Market Research & Insights FirmHQ: India (Mumbai, Delhi NCR) · UK (London)

Best for: CDSCO-aware HCP surveys and KOL mapping across India’s leading academic medical centres, Ayushman Bharat/PM-JAY payer research, and India-wide multilingual physician and patient fieldwork

BioNixus is a specialist healthcare market research company serving India-based and global pharmaceutical, biotech, and medtech clients. Ranked #1 in India for CDSCO-aware primary healthcare research, with deep public and private payer intelligence, KOL mapping at AIIMS, Tata Memorial Hospital, PGIMER Chandigarh, and CMC Vellore, and multilingual fieldwork capability across India's Tier-1, Tier-2, and Tier-3 cities.

Key strengths

CDSCO- and New Drugs and Clinical Trials Rules 2019-aware HCP survey design
Ayushman Bharat/PM-JAY and state health scheme payer research
ICMR guideline-aligned health outcomes and real-world evidence research
Multilingual fieldwork across India’s 22 official languages and Tier-1/2/3 cities
KOL identification and advisory board recruitment across AIIMS, Tata Memorial Hospital, PGIMER Chandigarh, and CMC Vellore
Specialist healthcare and pharma focus, not a generalist agency treating healthcare as one vertical among many
Global benchmarking: Indian studies connect to the USA, UK, EU5, UAE, and Southeast Asia with consistent instruments

IQVIA India

Global Healthcare Data & Analytics CompanyHQ: Gurugram / Bengaluru, India

Best for: Prescription analytics and market data, real-world evidence and secondary data, clinical trial operations support

IQVIA India is one of the largest healthcare data, technology, and CRO operations in the country, providing prescription analytics, real-world evidence, and clinical trial support for pharmaceutical clients. Deep secondary data and analytics infrastructure, though its scale is weighted toward data services and CRO delivery rather than bespoke primary market research.

Key strengths

Prescription analytics and market data across Indian states
Real-world evidence and longitudinal patient data analytics
Clinical trial operations and CRO-adjacent services
Large-scale secondary pharmaceutical intelligence for the Indian market

Kantar Health India

Global Market Research NetworkHQ: Mumbai, India (Kantar global)

Best for: HCP panel surveys, brand tracking, patient journey research

Kantar Health India is the healthcare research practice of Kantar in India, built in part on the legacy of IMRB (Indian Market Research Bureau), one of India’s oldest research organisations before its integration into the global Kantar network. Provides HCP panel surveys, brand health tracking, and patient journey research with broad national reach.

Key strengths

HCP panel surveys drawing on long-established Indian fieldwork infrastructure
Brand health tracking across Indian pharmaceutical and consumer health segments
Patient journey and longitudinal health panel research
Global benchmarking infrastructure via the Kantar network

Ipsos Healthcare India

Global Market Research NetworkHQ: Mumbai / Delhi NCR, India

Best for: HCP and patient panel surveys, consumer health research, brand and awareness tracking

Ipsos Healthcare India is the pharmaceutical and healthcare division of Ipsos India, offering HCP surveys, patient research, and brand tracking with access to the wider global Ipsos panel network. Established Indian presence with strong quantitative fieldwork capability across major metro markets.

Key strengths

HCP panel surveys across major Indian metro markets
Consumer health and patient perception research
Brand tracking and awareness studies for pharma and consumer health clients
Access to global benchmarking through the wider Ipsos network

Indegene

India-Headquartered Life Sciences Commercialization FirmHQ: Bengaluru, India

Best for: Digital-first commercialization support, HCP engagement platforms, life sciences content and analytics services

Indegene is a well-known India-headquartered life sciences commercialization and technology company, providing digital engagement platforms, content services, and analytics support to pharmaceutical and biotech clients globally. Primary research is one part of a broader technology-enabled commercialization offering rather than its core focus.

Key strengths

India-headquartered life sciences technology and commercialization scale
Digital HCP engagement platforms and omnichannel content services
Analytics and data services supporting global pharma commercial teams
Established global life sciences client relationships from an Indian delivery base

KOL Mapping and HCP Research Across India

India's academic medical centre network concentrates much of the country's most influential specialist opinion leadership and innovative prescribing. Key research environments include: AIIMS (All India Institute of Medical Sciences), with its flagship New Delhi campus and additional campuses across the country — India's foremost public medical research and teaching institution; Tata Memorial Hospital (Mumbai) — India's leading cancer research and treatment centre and a major oncology KOL hub; PGIMER Chandigarh (Postgraduate Institute of Medical Education and Research) — a leading multi-specialty academic and research centre for North India; and CMC Vellore (Christian Medical College) — one of India's oldest and most respected medical institutions, with particular influence across South India.

KOL mapping in India requires tracking influence across a large, federated, and linguistically diverse landscape. Delhi-based KOLs at AIIMS frequently hold national guideline committee roles; Mumbai-based specialists at Tata Memorial Hospital carry outsized influence in oncology; North Indian KOLs at PGIMER Chandigarh and South Indian KOLs at CMC Vellore often hold strong regional influence within their specialty areas. Effective KOL research maps influence by institution, region, language, and therapy area — not just publication volume.

HCP surveys in India require CDSCO- and ICMR-aware protocols, verified physician recruitment, and careful data handling. India's scale and diversity mean that representative pan-India physician research requires stratified recruitment across Tier-1, Tier-2, and Tier-3 cities, and multilingual fieldwork capability across major regional languages rather than English alone.

BioNixus conducts KOL mapping and HCP research across India in oncology, cardiovascular, infectious disease, metabolic, and other priority therapy areas — with CDSCO- and ICMR-aware methodologies and India-wide multilingual recruitment. See our Indian pharmaceutical market research guide and Indian healthcare market research overview for methodology details.

Methodology & Selection Criteria

This guide profiles firms with demonstrated healthcare and pharmaceutical market research operations in India as of 2026. Selection criteria: (1) active Indian operations with verified HCP and/or payer research capability, (2) relevance to healthcare, pharmaceutical, or consumer health buyers, (3) established track record in Indian healthcare market research. Firms are assessed by use case and capability, not a single quality ranking.

This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

Frequently Asked Questions

Who are the top healthcare market research companies in India in 2026?

The leading healthcare market research companies in India for 2026 are: BioNixus (global insights firm with CDSCO-aware HCP surveys, Ayushman Bharat/PM-JAY payer research, KOL mapping across India’s top academic medical centres, and India-wide multilingual fieldwork), IQVIA India (prescription analytics and real-world evidence), Kantar Health India (HCP panel surveys and brand tracking, built in part on the legacy of IMRB), Ipsos Healthcare India (HCP and patient panel research), and Indegene (India-headquartered life sciences commercialization and digital engagement). For custom primary research requiring CDSCO-aware study design, Ayushman Bharat/PM-JAY payer intelligence, KOL mapping, or multilingual India-wide fieldwork, BioNixus offers full-service delivery.

What is healthcare market research in India?

Healthcare market research in India is the systematic study of HCP attitudes, payer dynamics, patient behaviour, and competitive landscapes within India's health system. The Indian market is shaped by the Ministry of Health and Family Welfare and CDSCO (Central Drugs Standard Control Organisation) under the Drugs Controller General of India (DCGI) for drug and device regulation, ICMR (Indian Council of Medical Research) for research guidelines and ethics, the Ayushman Bharat/PM-JAY government health insurance scheme extending coverage to hundreds of millions of citizens, and a large, fast-growing private healthcare and insurance sector. Effective healthcare market research in India must also account for the country's linguistic and regional diversity — 22 official languages and a health system that varies significantly across Tier-1 metro, Tier-2, and Tier-3 city markets.

How do CDSCO and ICMR shape healthcare market research in India?

CDSCO (Central Drugs Standard Control Organisation), led by the Drugs Controller General of India (DCGI), regulates the approval, licensing, and post-market surveillance of drugs and medical devices in India under the New Drugs and Clinical Trials Rules 2019. ICMR (Indian Council of Medical Research) sets national ethical guidelines for biomedical and health research involving human participants. Healthcare market research for India must be designed with awareness of CDSCO regulatory milestones and timelines, and must follow ICMR-aligned ethical standards for informed consent, data protection, and responsible conduct of research involving physicians and patients.

What payer research does BioNixus conduct for Indian healthcare clients?

BioNixus conducts payer and health-financing research across India's mixed public-private system: Ayushman Bharat/PM-JAY, the government's flagship health insurance scheme covering a large share of India's population for secondary and tertiary hospitalisation; state-level health insurance schemes that operate alongside the national programme; and the private health insurance sector, which continues to expand alongside rising urban healthcare spending. Research covers scheme awareness and utilisation among providers and patients, private insurer perceptions, and market access intelligence to support pricing and access strategy across India's public and private channels.

How much does healthcare market research cost in India?

Custom healthcare market research costs in India are generally more accessible than in Western Europe or North America on a per-interview basis, though multilingual, multi-city programmes covering Tier-1, Tier-2, and Tier-3 markets require larger fieldwork investment than single-city or single-language studies. Specialist consultant surveys at leading academic medical centres and KOL mapping programmes command a premium due to limited respondent availability. Full mixed-method programmes (HCP surveys plus payer depth interviews plus advisory boards) require greater investment than single-method studies, and CDSCO/ICMR-aligned ethical review adds rigour and lead time compared to non-compliant alternatives.

Is BioNixus CDSCO- and ICMR-aware for HCP research in India?

Yes. BioNixus designs Indian HCP and patient research with awareness of CDSCO regulatory processes under the New Drugs and Clinical Trials Rules 2019 and ICMR ethical guidelines for research involving human participants. This includes appropriate informed consent procedures, ethics committee considerations where relevant, and careful data handling for physician and patient research. This regulatory awareness is essential for research involving Indian HCPs, patients, and health system stakeholders, and is a prerequisite for credible pharmaceutical and biotech research programmes in India.

What are the key Indian academic medical centres for KOL research?

The leading Indian academic medical centres and research hospital networks for KOL research and specialist HCP access include: AIIMS (All India Institute of Medical Sciences), with its flagship campus in Delhi and additional campuses across the country — India's foremost public medical research and teaching institution; Tata Memorial Hospital (Mumbai) — India's leading cancer research and treatment centre and a major oncology KOL hub; PGIMER Chandigarh (Postgraduate Institute of Medical Education and Research) — a leading multi-specialty academic and research centre in North India; and CMC Vellore (Christian Medical College) — one of India's oldest and most respected medical institutions, particularly influential in South India. Together these institutions concentrate much of India's most influential specialist opinion leadership across oncology, cardiology, infectious disease, and other priority therapy areas.

Can Indian healthcare research connect to global benchmarking?

Yes. BioNixus designs Indian healthcare research to connect to global benchmarking programmes — allowing pharmaceutical and biotech clients to compare Indian HCP attitudes, payer dynamics, and market access conditions directly against the USA, UK, France, Germany, Spain, Italy, Canada, Brazil, Saudi Arabia, and the UAE using consistent survey instruments and analysis frameworks. India-specific adaptations (Ayushman Bharat/PM-JAY payer research, CDSCO regulatory alignment, multilingual Tier-1/2/3 fieldwork) are layered within globally consistent methodologies, enabling India-specific insight within a broader global strategic context.

Related Resources

Pharmaceutical Market Research India

CDSCO-aware pharmaceutical research covering HCP surveys, KOL mapping, Ayushman Bharat/PM-JAY payer research, and evidence strategy.

Healthcare Market Research India

Comprehensive Indian healthcare market research overview — HCP surveys, payer research, HEOR, and patient studies.

Top Market Research Companies India 2026

General and consumer market research firms across India for 2026.

India Healthcare Market Report

Market sizing, CDSCO/regulatory landscape, payer dynamics, and outlook for the Indian healthcare market.

Top Healthcare Market Research Companies USA 2026

Leading healthcare and pharmaceutical market research firms in the USA — IRB-compliant, US AMC KOL access, PBM payer research, and IRA intelligence.

Healthcare Market Research

Global healthcare and pharmaceutical market research services and capabilities overview.

Plan Healthcare Market Research in India

BioNixus delivers CDSCO-aware pharmaceutical and healthcare market research across India — HCP surveys at India's leading academic medical centres, KOL mapping, Ayushman Bharat/PM-JAY payer research, and India-wide multilingual fieldwork. Global standards. In-market Indian execution.

Request a Proposal View Indian Research Capabilities